Contact US

Please complete the form below if you have a question or comment.

Study Sponsor

This post is also available in: French German Dutch

Common potential risks associated with the TLD procedure include, but are not limited to, worsening of COPD symptoms (shortness of breath, increased cough, COPD exacerbations), coughing up blood tinged mucous, difficulty swallowing, chest pain, upset stomach or feeling of fullness, trouble processing food, and fever.

Nuvaira® Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).